Trial Profile
A Multicentre, EU-wide, Non-Interventional Post-Authorisation Study to Assess the Safety and Usage of Delamanid in Routine Medical Practice in Multidrug-Resistant Tuberculosis Patients
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Delamanid (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- 23 Jun 2016 New trial record